Assenagon Asset Management S.A. Cuts Stock Position in Bruker Co. (NASDAQ:BRKR)

Assenagon Asset Management S.A. decreased its position in shares of Bruker Co. (NASDAQ:BRKRFree Report) by 37.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 200,709 shares of the medical research company’s stock after selling 119,457 shares during the period. Assenagon Asset Management S.A. owned 0.15% of Bruker worth $14,748,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in shares of Bruker by 90.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 356 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 169 shares during the last quarter. Zions Bancorporation N.A. acquired a new position in Bruker during the 1st quarter valued at about $26,000. Altshuler Shaham Ltd purchased a new stake in Bruker in the fourth quarter valued at about $27,000. VisionPoint Advisory Group LLC boosted its holdings in Bruker by 145.0% in the third quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock worth $32,000 after acquiring an additional 303 shares in the last quarter. Finally, IFP Advisors Inc grew its stake in shares of Bruker by 67.8% during the second quarter. IFP Advisors Inc now owns 438 shares of the medical research company’s stock worth $32,000 after acquiring an additional 177 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Hermann Fritz Requardt sold 15,000 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the sale, the director now directly owns 23,147 shares in the company, valued at approximately $2,084,618.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 28.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Stifel Nicolaus increased their price objective on shares of Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, February 14th. Wells Fargo & Company started coverage on Bruker in a research report on Tuesday, December 19th. They issued an “equal weight” rating and a $72.00 target price on the stock. JPMorgan Chase & Co. upgraded Bruker from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $60.00 to $90.00 in a research note on Wednesday, February 14th. Wolfe Research assumed coverage on Bruker in a research note on Wednesday, December 13th. They set an “outperform” rating and a $80.00 price target on the stock. Finally, Citigroup raised their price objective on Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Bruker presently has an average rating of “Moderate Buy” and a consensus target price of $84.29.

Check Out Our Latest Stock Report on BRKR

Bruker Stock Performance

NASDAQ BRKR opened at $93.94 on Friday. Bruker Co. has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.99 and a current ratio of 1.80. The firm has a market capitalization of $12.93 billion, a P/E ratio of 32.17, a PEG ratio of 2.35 and a beta of 1.17. The stock has a 50-day simple moving average of $82.74 and a two-hundred day simple moving average of $71.26.

Bruker (NASDAQ:BRKRGet Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Bruker had a return on equity of 29.94% and a net margin of 14.41%. The company had revenue of $844.50 million during the quarter, compared to analysts’ expectations of $809.35 million. During the same period last year, the business earned $0.74 earnings per share. Bruker’s quarterly revenue was up 19.2% on a year-over-year basis. On average, equities analysts forecast that Bruker Co. will post 2.74 earnings per share for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a $0.05 dividend. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $0.20 dividend on an annualized basis and a yield of 0.21%. Bruker’s payout ratio is 6.85%.

Bruker Company Profile

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Recommended Stories

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKRFree Report).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.